Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
de Tena
Jaime García
JG
D015415:Biomarkers / Q000378:metabolism; D002097:C-Reactive Protein / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D015984:Causality; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D015986:Confounding Factors, Epidemiologic; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D018579:Patient Selection; D011110:Polymorphism, Genetic / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D012107:Research Design; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
D015415:Biomarkers; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein